Printer Friendly

The CDC estimates 46.2 million Adults in the US Smoke Cigarettes and that 70% of those Smokers Have a Desire to Quit, Representing a Large Potential Market for Smoking Cessation Products.

DUBLIN, Irelalnd -- Research and Markets (http://www.researchandmarkets.com/reports/c31650) has announced the addition of Opportunities in the Pharmacotherapy of Addiction to their offering.

In 2003, almost 18 million people in the United States abused or were dependent on alcohol, and almost 20 million were illicit drug users. Many people abuse both alcohol and drugs. But the single most common avoidable cause of morbidity and mortality in the United States, resulting in more than 440,000 deaths and more than $75 billion in direct medical costs each year, is smoking, according to the Centers for Disease Control and Prevention (CDC). The CDC estimates that 46.2 million adults in the United States smoke cigarettes and that 70% of those smokers have a desire to quit, representing a large potential market for smoking cessation products.

This report provides an overview of substance abuse and dependency and reviews current and emerging therapies for the treatment of addiction to alcohol, illicit drugs, and nicotine. In conclusion, it forecasts changes in the market that will increase opportunities for companies that develop pharmacotherapeutic treatments for addiction.

Business Implications

Although addiction to alcohol and illicit drugs is a significant problem that costs society hundreds of billions of dollars each year, only a limited number of treatments are available to address this problem. Until 2004, only two drugs (disulfiram (Odyssey Pharmaceuticals' Antabuse) and naltrexone (Barr Pharmaceuticals' ReVia, generics)) were approved in the United States for treatment of alcohol dependence, and until 2002, only three drugs (methadone (Roxane Laboratories' Dolophine, generics), naltrexone, and levomethadyl (Roxane Laboratories' Orlaam)) were approved for treatment of opioid dependence; levomethadyl has since been pulled from the market.

The 2004 approval and 2005 market introduction of acamprosate calcium (Forest Laboratories Campral) for treatment of alcohol dependence and the 2002 introduction of buprenorphine and buprenorphone/naloxone (Reckitt Benckisers Subutex and Suboxone, respectively) for treatment of opioid dependence are representative of changes occurring in the market for drug and alcohol addiction. It is expected that the market will continue to grow but it is anticipated that expansion will be slow owing to several societal factors.

An estimated 46 million adults in the United States smoke cigarettes, and smoking claims more than 440,000 lives each year. Several products for smoking cessation are already available, including many over-the-counter and prescription products for nicotine replacement therapy and the antidepressant bupropion (GlaxoSmithKlines Zyban).

It is forecast that the U.S. market for smoking cessation will continue to grow, fueled by the large percentage of smokers who have expressed a desire to quit. Significant need and market opportunity exist for a highly effective treatment, and additional non-nicotine products for smoking cessation have reached Phase III clinical trials, with more in earlier stages of development.

Companies mentioned:

--Alkermes

--Bristol-Myers Squibb

--Catalyst Pharmaceutical Partners

--DrugAbuse Sciences

--GlaxoSmithKline

--InterveXion Therapeutics

--Nabi Biopharmaceuticals

--Pfizer

--Sanofi-Aventis

--Xenova

--Yaupon Therapeutics

For more information visit http://www.researchandmarkets.com/reports/c31650
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 26, 2006
Words:485
Previous Article:BRATZ MOBILE(TM) Phones Launch at Wal-Mart; Manufacturer of Popular BRATZ(TM) Dolls First to Extend Brand to Unique Mobile Phone Offering.
Next Article:Companies Wishing to Enter the Field of Rheumatoid Arthritis Diagnostics should Aim to Develop a Tool with Both Strong Diagnostic Performance and...
Topics:


Related Articles
Smoking out the best way to quit smoking.
Selected annotated bibliography. (Featured CME Topic: Smoking Cessation).
Selected ongoing clinical trials (*).
An analysis of a healthy start smoking cessation program.
Effects of a brief training program for lay health volunteers to facilitate smoking cessation among African Americans.
Karen Gutierrez: global reviews of mass media campaigns for smoking cessation and youth tobacco use prevention: "comprehensiveness is the key".
Smoking cessation & women: it took Colleen Cayton, 65, seven tries and a total body detoxification before she finally quit smoking for good.
Strategies for quitting smoking: I'm so proud of you! You've decided to quit smoking. Whether this is the first time you've tried to quit or the...
The potential of behavior-change interventions to improve the HIV/AIDS survivorship experience: the example of smoking cessation.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters